Combination of ASTX660 with an oligomerized, highly bioactive TRAIL variant (KillerTRAIL, hereafter referred to as TRAIL) enhanced death receptor‐mediated cytotoxicity in all CRC cell lines tested (Fig. 2A). Here, TNFSF10 is linked to colorectal carcinoma.